Glyfloam Sustained-release Tablet 10/1000 mg
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
MFDS item code 202300142 · Approved 2023.01.06
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medicine helps control blood sugar levels in adults with type 2 diabetes when used in combination with dapagliflozin and metformin. It is designed to effectively manage blood sugar levels alongside dietary adjustments and exercise therapy. Special attention is required regarding the impact of dapagliflozin on cardiovascular event occurrence in patients with cardiovascular diseases or risk factors where blood sugar levels are poorly controlled. For detailed information, please refer to expert clinical trial information. Overall, this medicine is used to improve blood sugar control in patients with type 2 diabetes.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce the gastrointestinal adverse effects of metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medicine, the dose may be initiated at the patient's existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other antihyperglycemic agents. Because such a change may cause changes in blood glucose control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, treatment with this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This medicine can very rarely cause a dangerous condition called lactic acidosis, so patients with poor kidney function or serious infections, dehydration, etc., should not use it. Additionally, caution is needed as hypoglycemia may occur when taken in combination with insulin or sulfonylurea medications. Patients with moderate to severe kidney impairment, liver dysfunction, or significant heart disease should not take this medicine. This medicine should not be used by pregnant or breastfeeding women, nor by patients with hereditary lactose intolerance. Patients with reduced fluid volume or at risk of low blood pressure should consult a doctor before taking this medicine and monitor blood pressure and kidney function consistently during treatment. During treatment with this medicine, genital and urinary tract infections may occur, so medical personnel should be notified immediately if symptoms of infection arise. There may be a risk of vitamin B12 deficiency, so regular blood tests to check vitamin B12 levels are advisable during long-term use. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided while taking this medicine. If undergoing surgery or iodine contrast tests, the use of this medicine should be halted for a certain period, and it should only be resumed after ensuring normal kidney function. In case of overdose, appropriate treatment is needed, and particularly for the metformin component, blood dialysis may be helpful. Elderly patients commonly experience decreased kidney function, so dosage should be adjusted and kidney function regularly monitored. This medicine does not significantly affect driving or operating machinery, but caution is advised as dizziness may occur. Store out of reach of children and keep in the original container to prevent misuse or degradation of medicine quality.
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a tightly sealed container that protects it from air and moisture at a temperature between 1 to 30 degrees Celsius. This helps maintain the efficacy and safety of the medicine.
Yellow, biconvex, oval-shaped sustained-release film-coated tablet
30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Il-Yang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Donghwa Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.